1.2412 USD
-0.01 (-1.1%)
Overall CPHI gets a fundamental rating of 1 out of 10. We evaluated CPHI against 190 industry peers in the Pharmaceuticals industry. CPHI may be in some trouble as it scores bad on both profitability and health. CPHI has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
- In the past year CPHI has reported negative net income.
- CPHI had a positive operating cash flow in the past year.
- CPHI had negative earnings in each of the past 5 years.
- CPHI had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- CPHI's Return On Assets of -26.56% is in line compared to the rest of the industry. CPHI outperforms 55.26% of its industry peers.
- Looking at the Return On Equity, with a value of -56.58%, CPHI is in line with its industry, outperforming 48.42% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -26.56% | ||
| ROE | -56.58% | ||
| ROIC | N/A |
ROA(3y)-24.28%
ROA(5y)-20.29%
ROE(3y)-65.01%
ROE(5y)-57.47%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Profit Margin and Operating Margin and Gross Margin are not available for CPHI so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- CPHI does not have a ROIC to compare to the WACC, probably because it is not profitable.
- CPHI has more shares outstanding than it did 1 year ago.
- The number of shares outstanding for CPHI has been increased compared to 5 years ago.
- Compared to 1 year ago, CPHI has a worse debt to assets ratio.
2.2 Solvency
- Based on the Altman-Z score of -4.89, we must say that CPHI is in the distress zone and has some risk of bankruptcy.
- CPHI has a worse Altman-Z score (-4.89) than 64.21% of its industry peers.
- The Debt to FCF ratio of CPHI is 48.73, which is on the high side as it means it would take CPHI, 48.73 years of fcf income to pay off all of its debts.
- Looking at the Debt to FCF ratio, with a value of 48.73, CPHI is in the better half of the industry, outperforming 74.21% of the companies in the same industry.
- CPHI has a Debt/Equity ratio of 0.53. This is a neutral value indicating CPHI is somewhat dependend on debt financing.
- CPHI's Debt to Equity ratio of 0.53 is on the low side compared to the rest of the industry. CPHI is outperformed by 64.21% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.53 | ||
| Debt/FCF | 48.73 | ||
| Altman-Z | -4.89 |
ROIC/WACCN/A
WACC7.32%
2.3 Liquidity
- CPHI has a Current Ratio of 0.51. This is a bad value and indicates that CPHI is not financially healthy enough and could expect problems in meeting its short term obligations.
- With a Current ratio value of 0.51, CPHI is not doing good in the industry: 92.63% of the companies in the same industry are doing better.
- A Quick Ratio of 0.19 indicates that CPHI may have some problems paying its short term obligations.
- CPHI has a worse Quick ratio (0.19) than 93.68% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.51 | ||
| Quick Ratio | 0.19 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 74.70% over the past year.
- Looking at the last year, CPHI shows a very negative growth in Revenue. The Revenue has decreased by -29.64% in the last year.
- Measured over the past years, CPHI shows a very negative growth in Revenue. The Revenue has been decreasing by -16.15% on average per year.
EPS 1Y (TTM)74.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%81.84%
Revenue 1Y (TTM)-29.64%
Revenue growth 3Y-22.27%
Revenue growth 5Y-16.15%
Sales Q2Q%10.91%
3.2 Future
- No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for CPHI. In the last year negative earnings were reported.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
- 76.32% of the companies in the same industry are more expensive than CPHI, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 88.63 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
- No dividends for CPHI!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
CHINA PHARMA HOLDINGS INC / CPHI FAQ
Can you provide the ChartMill fundamental rating for CHINA PHARMA HOLDINGS INC?
ChartMill assigns a fundamental rating of 1 / 10 to CPHI.
What is the valuation status of CHINA PHARMA HOLDINGS INC (CPHI) stock?
ChartMill assigns a valuation rating of 1 / 10 to CHINA PHARMA HOLDINGS INC (CPHI). This can be considered as Overvalued.
What is the profitability of CPHI stock?
CHINA PHARMA HOLDINGS INC (CPHI) has a profitability rating of 1 / 10.